6 central facts about serum-free light chain testing for multiple myeloma
Most clinical guidelines now recommend serum in place of urine testing
This content has been independently produced by Ausdoc, made possible through sponsorship from the Binding Site
Multiple myeloma, a malignant disease of the plasma cells, accounts for about 10% of all haematological malignancies, according to data from the Australian Institute of Health and Welfare.
Several key pathology investigations can be performed in the primary care setting. In this article, Newcastle-based haematologist, Dr Wojt Janowski outlines a best-practice diagnostic approach.
He notes that most clinical guidelines now recommend serum over urine testing to confirm the presence of monoclonal protein, a hallmark feature of multiple myeloma.
